|
Q1 FY2025
As of Feb 28, 2025
|
Q4 FY2024
As of Nov 30, 2024
|
Q3 FY2024
As of Aug 31, 2024
|
Q2 FY2024
As of May 31, 2024
|
Q1 FY2024
As of Feb 29, 2024
|
Q4 FY2023
As of Nov 30, 2023
|
Q3 FY2023
As of Aug 31, 2023
|
Q2 FY2023
As of May 31, 2023
|
Q1 FY2023
As of Feb 28, 2023
|
Q4 FY2022
As of Nov 30, 2022
|
Q3 FY2022
As of Aug 31, 2022
|
Q2 FY2022
As of May 31, 2022
|
Q1 FY2022
As of Feb 28, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||
| Current Assets | |||||||||||||
| Cash | |||||||||||||
| Prepaid expenses | |||||||||||||
| Total Current Assets | |||||||||||||
| Cash held in trust account | |||||||||||||
| Total Assets | |||||||||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | |||||||||||||
| Current liabilities | |||||||||||||
| Accounts payable – related party | |||||||||||||
| Related Party | |||||||||||||
| Total accounts payable – related party | |||||||||||||
| Accrued expenses | |||||||||||||
| Advance by related party | |||||||||||||
| Other payables | |||||||||||||
| Extension loan – related party | |||||||||||||
| Related Party | |||||||||||||
| Total extension loan – related party | |||||||||||||
| Working capital loan – related party | |||||||||||||
| Related Party | |||||||||||||
| Total working capital loan – related party | |||||||||||||
| Total Current Liabilities | |||||||||||||
| Deferred underwriter discount | |||||||||||||
| Total Liabilities | |||||||||||||
| Class A ordinary shares subject to possible redemption; 2,207,300 shares (at $12.09 per share) as of February 28, 2025 and 4,663,957 shares (at $11.88 per share) as of November 30, 2024 | |||||||||||||
| Shareholders’ Deficit | |||||||||||||
| Common stock value | |||||||||||||
| Common Class A | |||||||||||||
| Common Class B | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total Shareholders’ Deficit | |||||||||||||
| Total Liabilities and Shareholders’ Deficit |
Loading...
